NCT03950609 2026-03-19
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT05746208 2026-03-17
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT04848337 2026-02-12
PLANE-PC
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT03290079 2025-12-22
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02678780 2025-07-24
TALENT
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed